Acorda Therapeutics, Inc.
ACOR
株式のランク
#39161
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
株価
$0.879
最終同期: 2024-05-07
時価総額
$582.38K
変化（1日）
9.88%
変化（1年）
8,690.00%
国
US
取引 Acorda Therapeutics, Inc. (ACOR)
カテゴリー
Healthcare
Acorda Therapeutics, Inc.（ACOR）の株式分割履歴
Acorda Therapeutics, Inc.株（シンボル：ACOR）は合計で2回の株式分割を実施しました。
最新の株式分割はJun 05, 2023に行われました。
Jan 04, 2021より前に購入されたACOR株は、現在0.0083333333333333ACOR株に相当します。
最新の株式分割はJun 05, 2023に行われました。
Jan 04, 2021より前に購入されたACOR株は、現在0.0083333333333333ACOR株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 2023-06-05 | 1:20 | x0.05 | x0.0083333333333333 |
| 2021-01-04 | 1:6 | x0.16666666666667 | x0.16666666666667 |
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 0 | - |
DE
|
|
| 0 | - |
DE
|
|
| 0 | - |
JP
|
|
| 0 | - |
CH
|
|
| 5 | x119 |
IN
|
